- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00425126
Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
May 25, 2010 updated by: West Penn Allegheny Health System
Effect of Procrit(Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
Delayed graft function (DGF) is a major complication following deceased donor renal transplantation.
The surgical procedure of harvesting a kidney from a cadaveric donor and implanting the kidney into the recipient inevitably causes some amount of injury.
While not always clinically significant, anywhere from 10-50% of transplant patients may develop DGF.
Ongoing research in animal models has demonstrated benefit with administration of erythropoietin.
The investigators propose to study the effect of Procrit(Epoetin Alfa) on delayed graft function in subjects undergoing kidney transplantation.
Study Overview
Study Type
Interventional
Enrollment (Actual)
76
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients presenting for kidney transplantation
- Age > 18
- Deceased donor kidney transplant
Exclusion Criteria:
- History of thrombosis or hypercoagulable state
- Receiving Coumadin or Heparin
- Hemoglobin >=14 g/dl
- Uncontrolled hypertension
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Decrease in Delayed Graft Function
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Richard J Marcus, MD, West Penn Allegheny Health System
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Primary Completion (Actual)
February 1, 2010
Study Completion (Actual)
February 1, 2010
Study Registration Dates
First Submitted
January 18, 2007
First Submitted That Met QC Criteria
January 18, 2007
First Posted (Estimate)
January 22, 2007
Study Record Updates
Last Update Posted (Estimate)
May 27, 2010
Last Update Submitted That Met QC Criteria
May 25, 2010
Last Verified
May 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC-4044
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delayed Graft Function
-
Institute of Liver and Biliary Sciences, IndiaCompletedBiliary Complications | Graft Function, Delayed
-
Schroppel, Bernd, M.D.Alexion PharmaceuticalsTerminatedDelayed Function of Renal TransplantUnited States
-
Prolong PharmaceuticalsCompletedDelayed Function of Renal TransplantUnited States
-
Prolong PharmaceuticalsWithdrawnDelayed Function of Renal Transplant
-
MARIO ABBUD FILHOUnknownDelayed Function of Renal TransplantBrazil
-
Ohio State UniversityBristol-Myers SquibbTerminatedDelayed Graft FunctionUnited States
-
McGill University Health Centre/Research Institute...Astellas Pharma Canada, Inc.Unknown
-
First Affiliated Hospital Xi'an Jiaotong UniversityUnknownDelayed Graft FunctionChina
-
Columbia UniversityCompletedImplant or Graft; RejectionUnited States
-
King Chulalongkorn Memorial HospitalRecruitingKidney Transplant; Complications | Delayed Graft Function | Kidney FunctionThailand
Clinical Trials on Epoetin Alfa
-
Hospital de Clinicas de Porto AlegreOswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RSCompletedComparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
-
M.D. Anderson Cancer CenterCompleted
-
MegalabsAzidus LaboratoriesNot yet recruitingAnemia of Chronic Kidney DiseaseUruguay
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.CompletedKidney Diseases | Anemia
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedBlood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Mammaplasty | Cardiovascular Surgical Procedures | Blood Transfusion, Autologous
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.Terminated
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.CompletedCritical Illness | Anemia
-
Johnson & Johnson Pharmaceutical Research & Development...Completed